Mercer Global Advisors
LCTX icon

Mercer Global Advisors’s Lineage Cell Therapeutics LCTX Stock Holding History

Mercer Global Advisors’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$155 Buy
+118
New +$163 ﹤0.01% 5936

Other funds holding LCTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fifth Third Bancorp
Fifth Third Bancorp Cincinnati, Ohio $61.7B AUM 33.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Mercer Global Advisors's LCTX Position: Q2 2026 in Review

Mercer Global Advisors opened a new position in Lineage Cell Therapeutics (LCTX) in Q2 2026: 118 shares worth $155. The stake represents ﹤0.01% of the portfolio and ranks #5936 among its holdings.

99 funds tracked by Wall St. Rank hold LCTX as of Q2 2026.

  • Mercer Global Advisors held 118 shares of Lineage Cell Therapeutics worth $155 as of Q2 2026.
  • Lineage Cell Therapeutics was a new Mercer Global Advisors position in Q2 2026.
  • Lineage Cell Therapeutics made up ﹤0.01% of Mercer Global Advisors's portfolio in Q2 2026, its #5936 holding.
  • 99 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2026.

Based on Mercer Global Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.